Literature DB >> 8042826

The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart.

A M Katz1.   

Abstract

Heart failure is a progressive condition with a 5-year survival of less than 50%. This poor prognosis, which can be reproduced by overloading the hearts of experimental animals, may reflect molecular abnormalities caused when overload stimulates adult cardiac myocytes to undergo hypertrophy. Because these terminally differentiated cells have little or no capacity to divide, hypertrophy represents an unnatural growth response; however, the mechanism by which overload shortens survival remains speculative. Modification of this unnatural growth response by converting enzyme inhibitors and nitrates, which have growth inhibitory as well as vasodilator effects, may contribute to the ability of these drugs to improve prognosis in patients with heart failure.

Entities:  

Mesh:

Year:  1994        PMID: 8042826     DOI: 10.7326/0003-4819-121-5-199409010-00009

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  25 in total

Review 1.  Pathophysiology of heart failure: a look at the future.

Authors:  R M Delgado; J T Willerson
Journal:  Tex Heart Inst J       Date:  1999

Review 2.  Transcriptional regulation by cAMP in the heart.

Authors:  F U Müller; J Neumann; W Schmitz
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

3.  Endoplasmic reticulum stress is involved in cardiac damage and vascular endothelial dysfunction in hypertensive mice.

Authors:  Modar Kassan; Maria Galán; Megan Partyka; Zubaida Saifudeen; Daniel Henrion; Mohamed Trebak; Khalid Matrougui
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04-26       Impact factor: 8.311

Review 4.  Molecular basis of functional myogenic specification of Bona Fide multipotent adult cardiac stem cells.

Authors:  Eleonora Cianflone; Iolanda Aquila; Mariangela Scalise; Pina Marotta; Michele Torella; Bernardo Nadal-Ginard; Daniele Torella
Journal:  Cell Cycle       Date:  2018-06-25       Impact factor: 4.534

5.  Anemia is associated with an increased central venous pressure and mortality in a broad spectrum of cardiovascular patients.

Authors:  Lennaert Kleijn; B Daan Westenbrink; Vincent M van Deursen; Kevin Damman; Rudolf A de Boer; Hans L Hillege; Dirk J van Veldhuisen; Adriaan A Voors; Peter van der Meer
Journal:  Clin Res Cardiol       Date:  2014-02-08       Impact factor: 5.460

6.  AlphaANP, AVP, and pituitary-thyroid axis in patients with congestive heart failure and acute respiratory failure.

Authors:  S Savastano; V Cannavale; R Valentino; A P Tommaselli; R Rossi; A Luciano; L Tauchmanovà; A Mariano; L Mazzitelli; V Macchia; G Lombardi
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

7.  Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy.

Authors:  J Narula; P Pandey; E Arbustini; N Haider; N Narula; F D Kolodgie; B Dal Bello; M J Semigran; A Bielsa-Masdeu; G W Dec; S Israels; M Ballester; R Virmani; S Saxena; S Kharbanda
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

Review 8.  Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure.

Authors:  Stuart B Prenner; Sanjiv J Shah; Clyde W Yancy
Journal:  Curr Atheroscler Rep       Date:  2016-08       Impact factor: 5.113

9.  Phosphatidylinositol 4,5-bisphosphate regulates CapZβ1 and actin dynamics in response to mechanical strain.

Authors:  Jieli Li; Brenda Russell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-09-16       Impact factor: 4.733

10.  MEF2C silencing attenuates load-induced left ventricular hypertrophy by modulating mTOR/S6K pathway in mice.

Authors:  Ana Helena M Pereira; Carolina F M Z Clemente; Alisson C Cardoso; Thais H Theizen; Silvana A Rocco; Carla C Judice; Maria Carolina Guido; Vinícius D B Pascoal; Iscia Lopes-Cendes; José Roberto M Souza; Kleber G Franchini
Journal:  PLoS One       Date:  2009-12-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.